Seamless Therapeutics

About

Seamless Therapeutics is a biotechnology company based in Dresden, Germany, founded in 2022. The company specializes in developing disease-modifying gene therapies by reprogramming programmable recombinases. This innovative approach allows for precise, large-scale edits to the human genome, targeting severe genetic diseases across a wide range of conditions. In 2024, Seamless Therapeutics expanded to the United States with a new office in Lexington, MA, to enhance its research and development efforts. The company has raised $25 million in seed financing to support its platform, with leadership that includes experienced professionals in gene therapy and genome editing. Seamless Therapeutics is focused on advancing gene editing technologies to address unmet needs in genetic disorders, building a pipeline of product candidates currently in early discovery and preclinical stages.